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ABSTRACT
Cannabinoid (CB) receptors are validated drug targets in the endocannabinoid
signaling system associated with a number of human pathologies, and the development of
novel and selective small molecule CB ligands is warranted. A lead molecule HL-010, a
member of the 4H-thieno[3,2-b]pyrrole-5-carboxamide class of compounds, was
previously identified through CB homology modeling and virtual screening protocols as a
potential high affinity ligand for cannabinoid receptors. Validation of the in silico data
was realized with the evaluation of both CB1 and CB2 receptor binding and functional
activity assessment: HL-010 was found to be a potent (~10 nM) and selective CB2
receptor agonist with more than 100-fold selectivity over CB1 receptors. Unfortunately,
its high lipophilicity limited its aqueous solubility, and prevented further evaluation in
animal models. The bioisostere, RS-DFA-6-2 containing the 4H-furo[3,2-b]pyrrole-5carboxamide scaffold, was synthesized and preliminary data showed similar CB2 binding
affinity (~18 nM) with modest selectivity (40 fold) compared to HL-010, with slightly
improved aqueous solubility. This thesis research discloses the design and synthesis of
four additional analogs modified at the carboyxamide group (7a-d) using RS-DFA-6-2 as
the parent scaffold. These compounds were tested against CB receptors using established
radioligand displacement assays. Analog 7a, predicted to have enhanced aqueous
solubility, was the only compound that demonstrated reasonable CB2 receptor potency
and selectivity when compared to CB1.
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INTRODUCTION
CANNABINOID RECEPTORS AND THE ENDOCANNABINOID SYSTEM
The endocannabinoid signaling system is implicated in a number of central and
peripheral physiologies and pathologies including, but not limited to: inflammation, acute
and chronic pain, neurodegenerative diseases, reproductive health, immune regulation,
and muscle movement and coordination (1). The endocannabinoid system is composed
primarily of two main receptor types known as cannabinoid receptor subtype 1 (CB1) and
cannabinoid receptor subtype 2 (CB2). Both CB1 and CB2 are G-protein-coupled
receptors (GCPRs) that can adopt multiple active conformations, allowing them to
regulate distinct signaling cascades. This process of using multiple active conformations
to signal different pathways is referred to as biased signaling (2).
CB1 and CB2 receptors exhibit distinct tissue and cellular expression patterns:
CB1 receptors are predominantly expressed in the brain and to a lesser extent in the
periphery, while CB2 receptors are prevalent in nearly all immune cells in addition to
their overexpression in activated glial cells in the central nervous system (3).
Cannabinoids like Δ9-tetrahydrocannabinol (Δ9-THC), which agonize both
cannabinoid receptor types, result in physiological effects attributed primarily to
centrally-expressed CB1 receptors. Studies have also shown CB2 agonists have large
potential as therapeutics for neuropathic pain, immune disorders involving inflammation,
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osteoporosis, and other pathologies without eliciting the psychoactive effects seen with
nonselective cannabinoids (4).
The design and development of selective small-molecule ligands for the CB
receptor family has been challenging due to the lack of X-ray structures. However, the
X-ray crystal structure of the human CB1 receptor in complex with the stabilizing
antagonist AM6538 has recently been reported (5). Molecular docking studies were also
performed to elucidate the binding modes of a diverse set of antagonists and agonists of
the CB1 receptor. Prior to the disclosure of the CB1 receptor X-ray structure, most drug
discovery efforts were based on the development and validation of CB homology models
based on related GPCRs like the bovine rhodopsin receptors and beta-adrenergic
receptors (6,7). Computational drug discovery efforts based on these homology models
enabled researchers to use virtual screening protocols to identify novel small molecule
“hit” compounds. These computational strategies served as predictive models to guide
drug discovery and development in hit-to-lead campaigns targeting the CB receptors (8).
Through in silico virtual screening in combination with homology modeling
conducted at the University of Mississippi (Professor Robert Doerksen), a selective CB2
agonist known as HL-010 was discovered (Figure 1). This molecule was synthesized and
tested in the UM NIH COBRE CORE-NPN in vitro Core for CB receptor binding and
functional activity. Based on the data, HL-010 was determined to be a selective (100fold vs CB1) and potent (~10 nM) CB2 agonist. HL-010 was also tested in vivo in mice
and showed no activity in the tetrad behavioral assay which measures locomotor activity,
catalepsy latency, change in rectal temperature, and hotplate latency. The absence of
activity suggested that this molecule did not produce any collateral CB1 agonist effects
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(9). These results further demonstrated the potential for selective CB2 agonists as
therapeutics without the psychotropic effects. However, the formulation and
administration of HL-010 was difficult due to its limited aqueous solubility, a function of
its high LogP. In an effort to mitigate this detrimental physiochemical property,
additional analogs were considered. For example, RS-DFA-6-2, a bioisostere containing
the 4H-furo[3,2-b]pyrrole-5-carboxamide scaffold, was synthesized and CB receptor
binding data showed equivalent CB2 binding affinity (18 nM) with modest selectivity
(40 fold vs CB1) when compared to HL-010. However, the improvement in aqueous
solubility was only marginal.

Figure 1. Structures of selective CB2 ligands and associated CLogP values.

The aim of this thesis research was to design and synthesize of a library of RSDFA-6-2 analogs that were predicted to display greater water solubility profiles with a
retention of its CB2 affinity, selectivity, and functional activity (agonist). The research
described includes the synthesis and structure characterization of four carboxyamide
analogs of RS-DFA-6-2, their corresponding in vitro evaluation against CB1 and CB2
receptors, and functional activity assessment for the most promising analog(s).
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Methods
General Methods
All reagents and starting materials were purchased from Sigma-Aldrich (St. Louis, MO),
Acros Organics/Thermo Fisher Scientific (Waltham, MA). All anhydrous solvents were
purchased in bottles with molecular sieves (4Å). Air-free and moisture sensitive reactions
were carried out using standard air-free techniques in flame dried glassware under an argon
atmosphere. Thin-layer chromatography was utilized to monitor reactions with 225 μm
aluminum backed TLC plates coated with silica gel 60 F254 (EMD Millipore, Billerica,
MA). TLC plates were visualized with UV light (254 nm) and staining with ethanolic panisaldehyde, potassium permanganate, or phosphomolybdic acid stains. Mass
spectrometry (low resolution) experiments were performed on a Waters Micromass ZQ
single quadrupole mass spectrometer using either ESI positive (ESI+) or ESI negative
(ESI-) electrospray ionization. Proton (1H) and carbon (13C) NMR spectra were recorded
on Bruker 400 MHz Avance NMR spectrometers and processed using Mnova NMR
(Mestrelab Research).

(2): Ethyl 2-azidoacetate (Ref 10)
A solution of commercially available ethyl-2O

N3

CH3

bromoacetate (20 g, 0.12 mol) and acetone (125 mL)
O

was combined under standard conditions and then

4

cooled to 0°C. While stirring, a solution of sodium azide (19.5 g, 0.3 mol) in
water (100 mL) was added dropwise to the ethyl-2-bromoacetate solution. The
temperature was then increased to 63°C and remained stirring at 63°C for four
hours. The mixture was then cooled to room temperature, placed into a separation
funnel, and extracted 7x with 40 mL of ethyl acetate. The combined organic
fractions were then washed 3x with 20 mL of sodium bicarbonate and 3x with 10
mL of water. The organic layer was then dried over anhydrous sodium sulfate.
Following filtration, the solvent was removed from the filtrate under reduced
pressure and the residue was dried under vacuum to yield 15.0 grams (97 %) of 2.
MS(ESI+): m/z= 152.48 [M+Na]+

(3a): Methyl (Z)-2-azido-3-(furan-2-yl) acrylate (Ref 11)
H

Sodium ethoxide (4.8 g, 0.07 mol) was added to a

O

O

OCH3
N3

flask fitted with a pressure equalizer. Air was
evacuated from the flask and the system was then
kept under an argon atmosphere. Anhydrous

ethanol (39 mL) was added to the flask and cooled to -10 °C. The pressure
equalizer was charged with a solution containing 2-furaldehyde (1.49 mL, 0.018
mol) and compound 2 (9.0 g, 0.07 mol) dissolved in tetrahydrofuran (75 mL).
While the flask remained at -10 °C and with constant stirring, the solution was
added slowly over a period of 2 hours. The mixture was then continuously stirred
for an additional 2.5 hours at 0 °C. The resulting mixture was combined with ice
water, extracted three times with equal amounts of ethyl acetate, and then washed
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with water. The organic layer was dried over anhydrous sodium sulfate, filtered,
and the solvent was evaporated under reduced pressure. The residue was purified
using silica gel chromatography column with a mobile phase consisting of 10%
ethyl acetate/hexanes. The collected fractions containing the product were
combined and the solvent was removed under reduced pressure. Mass
spectrometry and NMR analysis confirmed the product structure.

Storage of the

purified product in the refrigerator for 3 days showed significant decomposition.
1H

NMR: (400 MHz, Chloroform-d) δ 7.49 (s, 1H), 7.10 (s, 1H), 6.86 (s, 1H),

6.53 (d, J = 1.6 Hz, 1H), 3.89 (s, 3H). 13C NMR: (101 MHz, Chloroform-d) δ
177.81, 152.90, 148.08, 121.14, 112.57, 77.45, 77.14, 76.82, 29.60.

(3b): Methyl (Z)-2-azido-3-(furan-2-yl) acrylate (Ref 11)
Sodium methoxide (1.69 g, 0.031 mol) was added to into a flask fitted with a
pressure equalizer. Air was evacuated from the flask and the system was then
kept under an argon atmosphere. Anhydrous methanol (24.5 mL) was added to
the flask and cooled to -10°C. Over a period of two hours, a mixture of
anhydrous tetrahydrofuran (33.4 mL), 2-furaldehyde (0.72 mL, 0.009 mol), and
ethyl-2-azidoacetate (4.0 g, 0.03 mol) was added to the flask with constant
stirring. The mixture was then continuously stirred for an additional 2.5 hours at
0 °C. The resulting mixture was combined with ice water, extracted three times
with equal amounts of ethyl acetate, and then washed with water. The organic
layer was dried over anhydrous sodium sulfate, filtered, and then the solvent was
evaporated under reduced pressure. The residue was purified using silica gel
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chromatography column with a 10% ethyl acetate/hexanes solution as the mobile
phase. The collected fractions from the column were combined and the solvent
was removed under reduced pressure. This yielded 1.2 grams of compound 3.
MS(ESI+): m/z= 216.13 [M+Na]+.
1H

NMR: (400 MHz, Chloroform-d) δ 7.51, 7.12, 6.88, 6.55, 6.54, 3.90.

(4): Methyl 4H-furo[3,2-b] pyrrole-5-carboxylate (Ref 11)
An anhydrous toluene (75 mL) solution of
O

O

compound 3b (1.0 g, 5.18 mmol) was added to a
N
H

O

flask of boiling toluene (75 mL) slowly over one

H 3C

hour. The reaction was allowed to reflux for an
additional hour and then cooled to room temperature. The product was condensed
under reduced pressure and purified using silica gel chromatography with a
mobile phase consisting of 25% ethyl acetate/hexanes solvent system. The
solvent was removed under reduced pressure, and the product dried under high
vacuum. 390 milligrams of compound 4 were obtained.
MS(ESI+): m/z= 187.98 [M+Na]+
1H

NMR: (400 MHz, Chloroform-d) δ 9.08 (s, 1H), 7.51 (d, J = 2.2 Hz, 1H), 6.80

(dd, J = 1.7, 0.9 Hz, 1H), 6.45 (dd, J = 2.2, 1.0 Hz, 1H), 3.88 (d, J = 0.8 Hz, 3H).
13C

NMR: (101 MHz, CDCl3) δ 162.68, 148.71, 147.98, 128.96, 123.81, 98.91,

96.96, 77.35, 77.04, 76.72, 51.59.
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(5): methyl 4-(4-fluorobenzyl)-4H-furo[3,2-b] pyrrole-5-carboxylate (Ref 12)
O

A minimal amount of dimethylformamide (2.5 mL)

O

was used to dissolve compound 4 (200 mg, 1.21
N

O

mmol) in a flask and then cooled to 0°C. NaH
(60% in mineral oil; 145 mg, 3.63 mmol) was
F

added slowly to the flask while stirring and
cooling. The flask was then vacuumed and purged

with argon. The mixture was stirred at room temperature for one hour. 4fluorobenzylchloride (0.36 mL, 3.63 mmol) was then added dropwise and the
mixture continued to stir for an additional 3 hours. Water (10 mL) was added to
the mixture which was then added to a separatory funnel to be extracted with
toluene (3 x 10 mL) and washed with water (3 x 10 mL). The organic layer was
dried over anhydrous sodium sulfate and filtered. The solvent was removed under
reduced pressure and the crude product was purified using a silica gel
chromatography column with a 10% ethyl acetate/hexanes solvent system. This
yielded 165 milligrams of compound 5. This procedure was repeated on a 185
milligram scale and produced an additional 90 milligrams of compound 5.
MS(ESI+): m/z= 296.33 [M+ Na]+
1H

NMR: 1H NMR (400 MHz, Chloroform-d) δ 7.46 (d, J = 2.3 Hz, 1H), 7.24 –

7.10 (m, 2H), 6.99 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 0.8 Hz, 1H), 6.19 (dd, J = 2.2,
0.9 Hz, 1H), 5.60 (s, 2H), 3.81 (s, 3H).
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13C

NMR: (101 MHz, CDCl3) δ 163.43, 162.39, 160.98, 148.59, 145.97, 133.52,

132.96, 129.06, 128.98, 123.20, 115.60, 115.39, 99.08, 98.56, 77.34, 77.00, 51.19,
50.02.

(6): 4-(4-fluorobenzyl)-4H-furo[3,2-b] pyrrole-5-carboxylic acid
O

Compound 5 (220 mg, 0.80 mmol) was dissolved in

O
N

OH

3mL of tetrahydrofuran and added to a flask with a
stir bar. An aqueous solution of KOH (60 mg in 4
mL of water) was added to the flask while stirring.

F

The resulting mixture was allowed to reflux for 10

hours at 83°C. The tetrahydrofuran was removed under reduced pressure. The
aqueous solution was acidified with 5% hydrochloric acid and extracted three
times with 10mL of ethyl acetate. The compound was then washed with water (3
x 10mL), dried over anhydrous sodium sulfate, and filtered. The solvent was
removed under reduced pressure and yielded 172 mg of compound 6.
MS(ESI+): m/z= 282.36 [M+Na]+
1H

NMR: 1H NMR (400 MHz, Chloroform-d) δ 7.49 (d, J = 2.2 Hz, 1H), 7.32 –

7.10 (m, 2H), 7.07 – 6.90 (m, 3H), 6.17 (dd, J = 2.2, 1.0 Hz, 1H), 5.60 (s, 2H).
13C

NMR: (101 MHz, CDCl3) δ 166.87, 163.49, 161.04, 149.41, 146.01, 134.25,

129.19, 129.11, 115.65, 115.44, 100.75, 98.59, 77.33, 76.69, 50.18.
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General Procedure 7: Amine Coupling Reaction
A portion of purified 6 (25 mg, 96.44 µmol) was dissolved in anhydrous
tetrahydrofuran (2 mL) and stirred in a flask. Each variable amine group (1.5
equivalents) in dichloromethane (1 mL), water soluble carbodiimide (25 mg),
HOBT (21 mg), and DIEA (30 µL) were added to the stirring solution. The
mixture continued to stir at room temperature for 16 hours. The solvent was
removed under reduced pressure, then water (20 mL) was added to the flask.
Then, 1N HCl (5 mL) was added dropwise to the flask while cooling. The
mixture was extracted with ethyl acetate, washed with water, and washed with
brine. The organic layer was dried over sodium sulfate, filtered, and concentrated
under reduced pressure. The residue was purified using a silica gel column with a
50% ethyl acetate/ hexanes solvent system. The product was analyzed using mass
spectrometry and NMR spectroscopy prior to CB receptor evaluation.

(7a): 4-(4-fluorobenzyl)-N-((1r,3s,5R,7S)-3-hydroxyadamantan-1-yl)-4H-furo[3,2-b]
pyrrole-5-carboxamide
Synthesized via General Procedure 7 with 3-aminoO

O

N

1-hydroxyadamantane (24.2 mg, 144 µmol), yielding

NH

17.0 mg of 7a.
MS(ESI+): m/z= 409.52 [M+H]+
OH

F

1H

NMR: (400 MHz, Chloroform-d) δ 7.19 (d, J =

5.5 Hz, 2H), 6.98 (t, J = 8.7 Hz, 2H), 6.40 (s, 1H),
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6.16 (s, 1H), 5.66 (s, 1H), 5.58 (s, 2H), 2.31 (s, 2H), 2.06 (d, J = 10.2 Hz, 4H),
2.00 (s, 4H), 1.75 (d, J = 12.3 Hz, 4H), 1.65 (s, 2H), 1.26 (d, J = 7.1 Hz, 2H).
13C

NMR: (101 MHz, CDCl3) δ 161.99, 146.97, 145.79, 130.75, 129.33, 128.16,

115.48, 115.27, 98.75, 93.39, 77.33, 76.69, 69.24, 54.56, 49.28, 44.11, 40.48,
34.87, 30.66.
(7b): azepan-1-yl(4-(4-fluorobenzyl)-4H-furo[3,2-b] pyrrol-5-yl) methanone
Synthesized via General Procedure 7 with azepane
O

O

(14.3 mg, 16.30 µL, 144.8 µmol) yielding 26.9 mg of
N

N

7b.
MS(ESI+): m/z= 364.47 [M+Na]+
1H

F

NMR: 1H NMR (400 MHz, Chloroform-d) δ 7.37

(dd, J = 2.3, 1.1 Hz, 1H), 7.26 (d, J = 1.1 Hz, 0H), 7.20
– 7.09 (m, 2H), 7.01 – 6.90 (m, 2H), 6.30 – 6.19 (m, 1H), 5.35 (s, 2H), 3.57 (t, J =
6.0 Hz, 3H), 1.68 (s, 3H), 1.61 (d, J = 1.1 Hz, 1H), 1.43 (d, J = 1.1 Hz, 3H), 1.25
(s, 3H), 0.86 (d, J = 11.8 Hz, 1H).

(7c): (4-(4-fluorobenzyl)-4H-furo[3,2-b] pyrrol-5-yl)(morpholino) methanone
Synthesized via General Procedure 7 with morpholine
O

O

(12.6 mg, 144 µmol) yieldihng 24.7 mg of 7c.
N

N

MS(ESI+): m/z= 351.41 [M+Na]+
O

F

1H

NMR: 1H NMR (400 MHz, Chloroform-d) δ 7.39

(d, J = 2.2 Hz, 1H), 7.26 (s, 1H), 7.18 – 7.08 (m, 2H),

11

6.98 (t, J = 8.7 Hz, 2H), 6.31 – 6.20 (m, 2H), 5.35 (s, 2H), 3.68 (dd, J = 5.7, 3.9 Hz, 4H),
2.04 (s, 2H), 1.26 (t, J = 7.1 Hz, 2H).
13C

NMR: (101 MHz, CDCl3) δ 146.75, 129.28, 129.20, 115.56, 115.34, 98.56, 95.25,

77.32, 77.00, 76.68, 66.84, 49.69.

O

O
N

NH

(7d): N-(3,4-dihydroxyphenethyl)-4-(4fluorobenzyl)-4H-furo[3,2-b] pyrrole-5-carboxamide
Synthesized via General Procedure 7 with 23 mg of
compound 6 and 3-hydroxytyramine (20 mg, 133 µmol)

F

yielding 19.4 mg of 7d.
HO

OH

MS(ESI+): m/z= 417.41 [M+Na]+
1H

NMR: 1H NMR (400 MHz, Chloroform-d) δ 7.39 (d, J = 2.2 Hz, 1H), 7.14 (dd, J =

8.6, 5.4 Hz, 2H), 6.95 (t, J = 8.7 Hz, 2H), 6.78 (d, J = 8.0 Hz, 1H), 6.67 (d, J = 2.0 Hz,
1H), 6.56 (dd, J = 8.0, 2.0 Hz, 1H), 6.37 (s, 1H), 6.17 (d, J = 2.8 Hz, 1H), 5.97 (t, J = 6.0
Hz, 1H), 5.57 (s, 2H), 4.13 (q, J = 7.1 Hz, 1H), 3.54 (q, J = 6.7 Hz, 2H), 2.69 (t, J = 6.9
Hz, 2H), 1.27 (t, J = 7.1 Hz, 1H).
13C

NMR: (101 MHz, Chloroform-d) δ 163.04, 160.93, 147.49, 145.82, 144.17, 142.89,

133.50, 131.64, 130.87, 129.03, 126.77, 120.78, 115.53, 115.32, 98.78, 94.26, 50.02,
40.89, 34.96.
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Radioligand Displacement for Cannabinoid Receptor Subtypes.
Compounds evaluated in this assay were run in competition binding with both cannabinoid
receptor subtypes, CB1 and CB2. CB receptor binding screening was performed under the
following conditions: 10 μM of each compound from independent triplicate dilutions was
incubated with 1.70 nM (CB1) or 1.9 nM (CB2). The full agonist [3H]-CP 55,940, and 5 μg
of CB1 or 1 μg of CB2 membrane were incubated for 90 min at 37 °C with gentle agitation
in a 96-well plate in a 0.2 mL final volume of 50 mM Tris-HCl, 20 mM EDTA, 154 mM
NaCl, and 0.2% radioimmunoassay grade BSA, pH 7.4. The reaction was terminated via
rapid vacuum filtration through a UniFilter 96 GF/C filter (PerkinElmer Life Sciences Inc.,
Boston, MA, USA), presoaked with 0.3% polyethylenimine, followed by 10 washes with
50 mM Tris-HCl, pH 7.4, buffer containing 0.2% BSA. Filters were dried, 25 μL of
MicroScint20 was added, and the plates were read using a TopCount NXT microplate
scintillation counter (PerkinElmer Life Sciences Inc., Boston, MA, USA). Total binding
was defined as binding in the presence of vehicle (1.0 % DMSO). Nonspecific binding was
the binding observed in the presence of 10.0 μM CP-55,940. Specific binding was defined
as the difference between total and nonspecific binding. Percent displacement was
calculated using the following formula: 100-(specific binding of compound - nonspecific
binding) x (100/specific binding).
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Results and Discussion
Design and Synthesis of RS-DFA-6-2 Analogs
One of the more critical challenges associated with structure-activityrelationship (SAR) studies for GPCR drug design and discovery campaigns is to make
judicious changes to the lead molecule without altering its functional activity. This is
clearly denoted in Figure 2, where small structural modifications of CB2 receptor ligands
results in major reversals in their functional activities (13).

Figure 2. Consequences of minor structure changes on CB functional activity.
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Prior to the inclusion of the RS-DFA-6-2 scaffold in our SAR analysis, lead
compound HL-010 was identified through virtual screening methods, synthesized, and
evaluated against CB receptors. From these initial efforts, bioisosteric RS-DFA-6-2 was
synthesized and shown to have similar binding affinity to the CB2 receptor, but its
aqueous solubility was only marginally improved. RS-DFA-6-2 differs from HL-010
only with the substitution of an oxygen atom for a sulfur atom in the bicyclic ring system.
The synthesis of 4H-furo[3,2-b]pyrrole-5-carboxamide analogs commenced with
the initial synthesis of the scaffold as illustrated in Figure 3. Treatment of ethyl-2bromoacetate (1) with sodium azide resulted in the facile substitution reaction, resulting
in ethyl 2-azidoacetate (2). Reaction of 2-furaldehyde with 2 in a condensation reaction
afforded 2-azido acrylate (3). Heating a solution of 3 in toluene (Hemetsberger-Knittel
reaction) resulted in the formation of the fused bicyclic 4H-furo[3,2-b]pyrrole-5carboxylic acid ester (4). Alkylation of 4 with sodium hydride and 4-fluorobenzyl
chloride yielded the substitution product 5. Hydrolysis of the methyl ester of 5 with
potassium hydroxide afforded the product scaffold carboxylic acid 6. Mass spectrometry
and NMR spectroscopy analysis were employed to confirm the mass and structure of the
intermediates and final products.
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Figure 3. Synthesis 4-(4-fluorobenzyl)-4H-furo[3,2-b] pyrrole-5-carboxylic acid (6)
Reagents and conditions: (i) NaN3, Acetone, 63 °C, 4 h. (ii) NaOMe/MeOH, THF, 0 °C,
2.5 h. (iii) Toluene, reflux, 2 h. (iv) DMF, NaH, 25 °C, 3 h. (v) KOH, THF, H2O, 83 °C,
10 h.
The approach taken to design new analogs included a search of the primary
literature, examining molecules that have reported CB2 selective activity with good
aqueous solubility. The successful synthesis of the scaffold 6 allowed for the expedient
synthesis of new carboxyamide analogs. Four analogs were proposed for synthesis, and
included the reaction of scaffold 6 with various amines using standard coupling reactions
(Figure 4).
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Figure 4. Synthesis of Analogs. Reagents and Conditions: (vi) amine, THF, DCM,
WSC, HOBT, DIEA, 25°C, 16 h.
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The four new analogs (7a-7d) synthesized from scaffold 6 used the same general
reaction conditions while varying the nature of the amine group, illustrated in Figure 4.
Specifically, an amine-carboxylic acid coupling reaction was employed, in the presence of
HOBT as an activator to produce the analogs. The compounds were analyzed by mass
spectrometry for molecular weight confirmation, and by NMR analysis to confirm their
structure.
Table 1 depicts the structures of the analogs, their corresponding molecular
weights, and the calculated LogP values. The reduction in lipophilicity is evident from
calculated LogP values. Analog 7a, comprising a simple modification of RS-DFA-6-2
with the introduction of a hydroxyl group to the adamandtyl ring resulted in a dramatic
reduction in lipophilicity by 1.5 log units when compared to RS-DFA-6-2 (CLogP=5.3).
Analogs 7b and 7d are structurally dissimilar but also display lower CLogP values relative
to the parent molecule. The least lipophilic analog 7c (CLogP=2.2) would be expected to
exhibit the greatest aqueous solubility of the synthesized analogs.
Analog:

7a

7b

O

O
N

O

O
N

NH

7c
N

Structure:

O

O

O

O

N

7d
N

N

NH

O

OH
F

F

F

Molecular C24H25FN2O3
C20H21FN2O2
C18H17FN2O3
Formula:
Molecular 408.47
340.40
328.34
Weight:
CLogP
3.9
3.8
2.2
Table I. Synthesized Analogs and Calculated LogP values
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F
OH OH

C22H19FN2O4
394.40
3.5

These four analogs were screened for both cannabinoid and opioid receptor binding
activity. In the case of cannabinoid activity assessment, a radioligand competitive binding
assay was employed to measure the ability of ligands to displace the radioligand [3H]-CP55940 from CB1 and CB2 cannabinoid receptors and is commonly used as an initial step in
the assessment of efficacy of a cannabinoid receptor ligand. The binding data presented in
Table II is a result of experiments conducted by NIH COBRE CORE-NPN in vitro Core
scientists at the University of Mississippi; the assay protocols used were in accordance with
previously reported methods conducted by this Core (14).
Compound

CB1

CB2

7a

41.3%

92.2%

7b

43.6%

45.8%

7c

16.8%

5.4%

7d

75.7%

40.9%

Table II. Displacement of [3H]-CP55940 binding. 10 µM test compound against
human CB1 and CB2 receptors, expressed as percentage (%)

The preliminary screening data reveal several important findings. Analog 7a
displaced the largest percent displacement against CB2 receptors and reasonable
selectivity versus CB1 receptors. Analogs 7b, 7c, and 7d did not meet the threshold of
50% displacement in the CB2 receptor assay, and were not submitted for Ki evaluation.
It appears that major changes to the structure of the carboxyamide side chain negatively
influences binding to the CB2 receptor, and the presence of the adamantane ring (or
bioisostere) is recommended. Based on the CB receptor binding data, analog 7a showed
the most promise as a CB2 selective ligand. Since analog 7a exceeded the threshold of
18

CB2 percent displacement, additional studies were performed using serial dilutions of 7a
using the same assay to establish binding constants. The results are shown in Table III.
Analog 7a was approximately 10 fold less effective in binding to CB2 receptors that the
parent molecule RS-DFA-6-2 when the Ki values are compared. It also displays a
preferred selectivity for CB2 receptor binding versus CB1 receptors, similar to RS-DFA6-2.

Compound
CB1 (Ki, nM)
CB2 (Ki, nM)
682.9
18.1
RS-DFA-6-2
3.0
1.9
CP-55,940
>1000
115.0
7a
Table III. Ki values for test compounds against cannabinoid receptors. Compound
7a shows high affinity for the CB2 receptor (Ki= 115.0 ± 21.0 nM).

The results of this research help to define the structural requirements necessary to
maintain potent and selective ligand binding to cannabinoid receptors, as it pertains to
modification of the lead compound, RS-DFA-6-2. In an attempt to produce an analog
with increased aqueous solubility, four analogs were designed and evaluated against both
CB1 and CB2 receptors. Only one analog, 7a, exhibited reasonable potency and receptor
selectivity, with a calculated decrease in lipophilicity. Future research should be focused
on analogs related to 7a, namely, with the retention of a carboxyamide group containing
an adamantane ring or bioisosteric equivalent.
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